Advocacy intelligence hub — real-time data for patient organizations
The Royal Wolverhampton Hospitals NHS Trust
University Hospital, Basel, Switzerland — PHASE1
SWOG Cancer Research Network — PHASE3
University of Salamanca — NA
National Heart, Lung, and Blood Institute (NHLBI) — EARLY_PHASE1
Henan Cancer Hospital — PHASE2
City of Hope Medical Center — PHASE1
AstraZeneca — PHASE2
Paolo Caimi, MD — PHASE1
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance8
CALQUENCE
AstraZeneca
Venclexta
AbbVie
Campath
Sanofi
COPIKTRA
Secura Bio
ARZERRA
Novartis
Fludarabine Phosphate
Sanofi
TREANDA
Teva
Gazyva
Genentech
Campath
(alemtuzumab)Orphan drugstandardGenzyme Corporation
CD52-directed Cytolytic Antibody [EPC]
12.1 Mechanism of Action CAMPATH binds to CD52, an antigen present on the surface of B and T lymphocytes, a majority of monocytes, macrophages, NK cel...
CALQUENCE
(acalabrutinib)Orphan drugstandardAcerta Pharma, LLC (a member of the AstraZeneca Group)
Kinase Inhibitor [EPC]
12.1 Mechanism of Action Acalabrutinib is a small-molecule inhibitor of Bruton tyrosine kinase (BTK). Acalabrutinib and its active metabolite, ACP-586...
ARZERRA
(ofatumumab)Orphan drugstandardNovartis Pharmaceuticals Corporation
CD20-directed Cytolytic Antibody [EPC]
12.1 Mechanism of Action Ofatumumab binds specifically to both the small and large extracellular loops of the CD20 molecule. The CD20 molecule is expr...
COPIKTRA
(duvelisib)Orphan drugstandardSecura Bio, Inc.
12.1 Mechanism of Action Duvelisib is an inhibitor of PI3K with inhibitory activity predominantly against PI3K-δ and PI3K-γ isoforms expressed in norm...
Fludara
(Fludarabine phosphate)Orphan drugstandardBerlex Laboratories, Inc.
12.1 Mechanism of Action Fludarabine phosphate is rapidly dephosphorylated to 2-fluoro-ara-A and then phosphorylated intracellularly by deoxycytidine ...
Acetylcysteine
(ACETYLCYSTEINE)Orphan drugstandardHospira, Inc.
GAZYVA
(obinutuzumab)Orphan drugstandardGenentech Inc., a member of the Roche Group
CD20-directed Cytolytic Antibody [EPC]
12.1 Mechanism of Action Obinutuzumab is a monoclonal antibody that targets the CD20 antigen expressed on the surface of pre-B and mature B lymphocyte...
Bendeka
(bendamustine for 50 ml admixture)Orphan drugstandardEagle Pharmaceuticals, Inc.
12.1 Mechanism of Action Bendamustine is a bifunctional mechlorethamine derivative containing a purine-like benzimidazole ring. Mechlorethamine and it...
Cell surface thiol-disulfide regulation in cancer: Mechanisms, implications, and theranostic strategies.
Redox homeostasis is frequently disrupted in cancer and contributes to tumor progression, metastasis, and therapy resistance. This review focuses on how thioredoxin-1 (TXN1), thioredoxin reductase-1 (...
Impact of high-fat Western diet on chronic lymphocytic leukemia disease progression and gut microbiome profile in Eμ-TCL1 mice.
The composition and function of the gut microbiome have been shown to contribute to both health and disease. One of the most powerful modulators of microbial composition and function is diet. Using th...
Early-life B cell memory is archived in the mouse B-1 cell compartment and drives chronic lymphocytic leukemia-like disease.
The adult B cell pool is a mosaic comprising short-lived naive B cells and long-lived memory. Using genetic time stamping, we have previously shown that early-life-origin (ELO) B cells contribute subs...
Epigenetics in B-CLL.
B-cell chronic lymphocytic leukemia (B-CLL) is the most common hematological malignancy in adults. Its clinical course is heterogeneous, ranging from indolent forms with slow progression to aggressive...
Discovery of novel imidazo[4,5-b]pyridine derivatives as noncovalent reversible Bruton's tyrosine kinase inhibitors.
Bruton's tyrosine kinase (BTK) has emerged as a validated therapeutic target for B-cell malignancies and autoimmune disorders, and covalent BTK inhibitors have demonstrated remarkable clinical efficac...
Prof. Dr. Michael Schmitt
University Hospital Heidelberg, Department V
David Maloney
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
Adam J Olszewski, MD
Yale Cancer Center
📍 New Haven, Connecticut
Project Leader
Ono Pharmaceutical Co. Ltd
Farhad Ravandi-Kashani, MD, M.D
M.D. Anderson Cancer Center
📍 HOUSTON, TX
Ajay Gopal
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium
📍 SEATTLE, WA